Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBM22P12 is a pseudogene related to RNA binding motif protein 22 (RBM22). Unlike its protein-coding counterpart, pseudogenes like RBM22P12 do not produce functional proteins. There is no evidence that RBM22P12 is transcribed or translated, nor is it involved in cellular signaling or disease processes as a conventional drug target. Pseudogenes are generally considered non-functional remnants of genes that have lost their protein-coding ability due to mutations. Therefore, RBM22P12 is not considered a therapeutic target, and there are no known biological functions, disease roles, interacting drugs, or biomarker applications associated with it. The actual protein-coding RBM22 gene encodes an RNA-binding protein involved in pre-mRNA splicing and potentially cell division, but this information does not apply directly to the pseudogene RBM22P12. If searching for a drug target, refer to RBM22, not RBM22P12.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA binding motif protein 22 pseudogene 12 (RBM22P12).